- Conditions
- Mild Cognitive Impairment (MCI), Mild Alzheimer Disease, Memory Deficits
- Interventions
- home-based self-administered interactive exercise
- Device
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 3,752
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Haemophilia A
- Interventions
- Recombinant Factor VIII (Kovaltry, BAY81-8973)
- Biological
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 0 Years to 12 Years · Male only
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2020
- U.S. locations
- 4
- States / cities
- New Orleans, Louisiana • Cincinnati, Ohio • Cleveland, Ohio + 1 more
- Conditions
- Sarcoidosis
- Interventions
- all subjects will receive maraviroc 300mg orally twice a day for 6 weeks, Bronchoscopy with bronchoalveolar lavage, venipunctures, Skin biopsy
- Drug · Procedure
- Lead sponsor
- Kevin F. Gibson
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Opioid-use Disorder
- Interventions
- Core Intervention, Peer Support Specialists (PSS), Treatment as Usual (TAU)
- Behavioral
- Lead sponsor
- Brown University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 3
- States / cities
- Durham, North Carolina • Philadelphia, Pennsylvania • Providence, Rhode Island
- Conditions
- Primary Central Nervous System Lymphoma (PCNSL), Primary Central Nervous System Lymphoma, Relapsed Primary Central Nervous System Lymphoma, Refractory Primary Central Nervous System Lymphoma, Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma (SCNSL)
- Interventions
- ibrutinib, Epcoritamab
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 8
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more
- Conditions
- Non-ST Elevation Acute Coronary Syndrome
- Interventions
- ticagrelor, clopidogrel
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 8
- States / cities
- Jacksonville, Florida • Lake Mary, Florida • Macon, Georgia + 5 more
- Conditions
- Hypogonadism
- Interventions
- TSX-002
- Drug
- Lead sponsor
- TesoRx Pharma, LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Myelodysplastic Syndrome
- Interventions
- Erlotinib
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Graft Vs Host Disease, Graft-versus-host-disease, Graft Versus Host Disease
- Interventions
- Ruxolitinib, Abatacept
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Hepatitis C Infection
- Interventions
- ITX 5061
- Drug
- Lead sponsor
- Schiano, Thomas D., MD
- Other
- Eligibility
- 18 Years to 72 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Influenza
- Interventions
- Peramivir, Placebo
- Drug
- Lead sponsor
- BioCryst Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 96
- States / cities
- Millbrook, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 80 more
- Conditions
- Head and Neck Cancer
- Interventions
- Valproic Acid
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Leukemia-Lymphoma, Adult T-Cell
- Interventions
- Bortezomib, Etoposide, Vincristine, Doxorubicin, Prednisone, Cyclophosphamide, Raltegravir
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 6
- States / cities
- Miami, Florida • Baltimore, Maryland • St Louis, Missouri + 2 more
- Conditions
- Segmental Long Bone Defects
- Interventions
- Autogenous RIA bone grafting, Allogeneic bone grafting
- Procedure
- Lead sponsor
- The University of Texas Medical Branch, Galveston
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 1
- States / cities
- Galveston, Texas
- Conditions
- Gastric Cancer, Gastric Adenocarcinoma
- Interventions
- Rivoceranib, Placebo
- Drug
- Lead sponsor
- Elevar Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 460 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 5
- States / cities
- Scottsdale, Arizona • Rogers, Arkansas • Detroit, Michigan + 2 more
- Conditions
- Gait
- Interventions
- Gait Training, Functional electrical stimulation (FES), Peripheral electrical stimulation paired with cortical magnetic stimulation pulses
- Other · Device
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Severe Acute Respiratory Syndrome
- Interventions
- Camostat Mesilate, Standard of Care
- Drug · Other
- Lead sponsor
- Alan Bryce
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 2
- States / cities
- Scottsdale, Arizona • Tucson, Arizona
- Conditions
- Ear Barotrauma, Middle Ear Disease, Ear Diseases, Pressure Injury, Eustachian Tube Dysfunction, Middle Ear; Injury, Middle Ear Barotrauma
- Interventions
- Compression Profile/Schedule: 15 minute Non-Linear compression from start of the daily treatment until treatment pressure is reached (45 fsw), Compression Profile/Schedule: 15 minute Linear compression from start of the daily treatment until treatment pressure is reached (45 fsw)
- Procedure
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- Not listed
- Enrollment
- 1,553 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Sleepy Hollow, New York
- Conditions
- Cystic Fibrosis
- Interventions
- Ataluren (PTC124®), Placebo
- Drug
- Lead sponsor
- PTC Therapeutics
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 279 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Long Beach, California + 23 more
- Conditions
- Urea Cycle Disorders, Carbamoyl-Phosphate Synthase I Deficiency
- Interventions
- LNP.UCD.ABE
- Biological
- Lead sponsor
- Rebecca Ahrens-Nicklas
- Other
- Eligibility
- 24 Hours to 5 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Diabetic Macular Edema(DME)
- Interventions
- YD312 50mg, YD312 150mg, YD312 350mg, Placebo
- Drug
- Lead sponsor
- YD Global Life Science Co., Ltd.
- Industry
- Eligibility
- 19 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Hialeah, Florida • Lakeland, Florida + 10 more
- Conditions
- Foot Ulcer, Diabetic
- Interventions
- Once-daily remote foot temperature monitoring
- Device
- Lead sponsor
- Kaiser Permanente
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 3
- States / cities
- Kensington, Maryland • Upper Marlboro, Maryland • Springfield, Virginia
- Conditions
- Colon Polyps, Colorectal Cancer, Inflammatory Bowel Disease (IBD)
- Interventions
- Colon KCC Heptapeptide
- Biological
- Lead sponsor
- Danielle Kim Turgeon
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Myelodysplastic Syndrome (MDS), Chronic Lymphocytic Leukemia (CLL), Chemotherapy-sensitive Lymphoma, Acute Lymphoblastic Leukemia (ALL)/T Lymphoblastic Lymphoma, Acute Myelogenous Leukemia (AML), Acute Biphenotypic Leukemia (ABL), Acute Undifferentiated Leukemia (AUL)
- Interventions
- Fludarabine, Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5, Total Body Irradiation (TBI) 200cGy on Day -1, Infusion of non-T-cell depleted bone marrow on Day 0, Busulfan, Cyclophosphamide 50mg/kg/day IV on Days -2,-1, Cyclophosphamide 50mg/kg/day IV on Days -5,-4, Total Body Irradiation (TBI) 200cGy twice a day on Days -3, -2, -1, Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4, Sirolimus, Mycophenolate mofetil, G-CSF, Pre-HCT Mesna on Days -6 and -5, Pre-HCT Mesna on Days -2 and -1, Pre-HCT Mesna on Days -5 and -4, Post-HCT Mesna
- Drug · Radiation · Procedure
- Lead sponsor
- Center for International Blood and Marrow Transplant Research
- Network
- Eligibility
- 15 Years to 70 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 11
- States / cities
- Gainesville, Florida • Miami, Florida • Tampa, Florida + 7 more